Cited by 31Pharmacogenetics and Drug MetabolismDialysis and Renal Disease ManagementPolyamine Metabolism and Applications

Decreased Kidney Function Is Associated with Enhanced Hepatic Flavin Monooxygenase Activity and Increased Circulating Trimethylamine N-Oxide Concentrations in Mice

Open access
Johnson, Cassandra, Prokopienko, Alexander J., West, Raymond E., Nolin, Thomas D., Stubbs, Jason R.·2018·Drug Metabolism and Disposition

Abstract

Circulating trimethylamine N-oxide (TMAO) predicts poor cardiovascular outcomes in patients with chronic kidney disease (CKD). Accumulation of serum TMAO has been observed in CKD patients; however, the mechanisms contributing to this finding have been inadequately explored. The purpose of this study was to investigate the mechanisms responsible for TMAO accumulation in the setting of decreased kidney function using a CKD mouse model. Mice were fed a diet supplemented with 0.2% adenine to induce CKD, which resulted in increased serum TMAO concentrations (females: CKD 29.4 ± 32.1 μ M vs. non-CKD 6.9 ± 6.1 μ M, P < 0.05; males: CKD 18.5 ± 13.1 μ M vs. non-CKD 1.0 ± 0.5 μ M, P < 0.001). As anticipated, accumulation of circulating TMAO was accompanied by a decrease in renal clearance (females: CKD 5.2 ± 3.8 μ l/min vs. non-CKD 90.4 ± 78.1 μ l/min, P < 0.01; males: CKD 10.4 ± 8.1 μ l/min vs. non-CKD 260.4 ± 134.5 μ l/min; P < 0.001) and fractional excretion of TMAO. Additionally, CKD animals exhibited an increase in hepatic flavin monooxygenase (FMO)-mediated formation of TMAO (females: CKD 125920 ± 2181 pmol/mg per 60 minutes vs. non-CKD 110299 ± 4196 pmol/mg per 60 minutes, P < 0.001; males: CKD 131286 ± 2776 pmol/mg per 60 minutes vs. non-CKD 74269 ± 1558 pmol/mg per 60 minutes, P < 0.001), which likely resulted from increased FMO3 expression in CKD mice. The current study provides evidence that both decreased renal clearance and increased hepatic production of TMAO may contribute to increments in serum TMAO in the setting of CKD. Hepatic FMO activity may represent a novel therapeutic target for lowering circulating TMAO in CKD patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1124/dmd.118.081646

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • These observations have been replicated in multiple independent observational cohorts across a spectrum of CKD patients.

    “These observations have since been replicated in multiple independent observational cohorts across a spectrum of CKD patients199–203.”

    From Dietary metabolism, the gut microbiome, and heart failure (2019) · cites this paper as [200]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Johnson, C., Prokopienko, A. J., West, R. E., Nolin, T. D., & Stubbs, J. R.
Affiliations
University of Pittsburgh (US)
Venue
Drug Metabolism and Disposition
Publisher
Elsevier BV
Published
2018-09
Volume
46
Issue
9
Pages
1304-1309
ISSN
0090-9556 (ISSN-L)
OpenAlex
W2809440501
Cited by
31
References
31
Citations by year
2026: 1 · 2025: 3 · 2024: 3 · 2023: 5 · 2022: 2 · 2021: 3 · 2020: 5 · 2019: 7 · 2018: 2
FWCI
4.68
Type
journal article
Language
en
Open access
Locations
  • Drug Metabolism and Disposition (publishedVersion)
  • PubMed (publishedVersion)
Funders
American Heart Association (15GRNT25700231)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Polyamine Metabolism and Applications
Keywords
trimethylamine N-oxide, chronic kidney disease, flavin-containing monooxygenase, FMO3, adenine-induced CKD, cardiovascular risk, gut microbiota metabolites
MeSH terms
Animals, Enzyme Activation, Female, Kidney, Male, Methylamines, Mice, Inbred C57BL, Microsomes, Liver, Oxygenases, Hepatocytes, Mice, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review